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Nephrotic syndrome is a disorder of the glomerular ﬁltration barrier, and central to
the ﬁltration mechanism of the glomerular ﬁltration barrier is the podocyte. We are
starting to better understand how this cell, with its unique architectural features,
fulﬁls its exact ﬁltration properties. The multiprotein complex between adjacent
podocyte foot processes, the slit diaphragm, is essential to the control of the actin
cytoskeleton and cell morphology. Many of the proteins within the slit diaphragm,
including nephrin, podocin, transient receptor potential-6 channel, and a-actinin-4,
have been identiﬁed via genetic studies of inherited nephrotic syndromes. Signaling
from slit diaphragm proteins to the actin cytoskeleton is mediated via the Rho
GTPases. These are thought to be involved in the control of podocyte motility, which
has been postulated as a focus of proteinuric pathways. Nephrotic syndrome is
currently treated with immunosuppressive therapy, with signiﬁcant adverse effects.
These therapies may work in nephrotic syndrome due to speciﬁc effects on the
podocytes. This review aims to describe our current understanding of the cellular
pathways and molecules within the podocyte relevant to nephrotic syndrome and its
treatment. With our current knowledge of the cellular biology of the podocyte, there
is much hope for targeted therapies for nephrotic syndromes.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The nephrotic syndrome (NS) describes a triad of hypoal-
buminemia, edema, and proteinuria. It is the most common
glomerular disease of childhood and has an incidence of
approximately 2:100,000 [1].
NS may be classiﬁed by response to steroids—steroid respon-
sive and steroid resistant. It is possible that a different patho-
physiology underlies these different subgroups; however, this
does not explain those who are initially responsive but later
become resistant. Minimal-change nephropathy is reported asrean Society of Nephrology. P
ses/by-nc-nd/4.0/).
, Learning and Research
spital, Bristol BS10 5NB,
aleem).the most common cause of NS in children (approximately 80% of
cases) according to the International Study of Kidney Disease in
Children (1967–1974). Most of these will be steroid responsive.
Approximately 20% of NS will be clinically steroid resistant
[steroid-resistant NS (SRNS)]. and about 60% of these will have
focal segmental glomerulosclerosis (FSGS) on biopsy. Those with
FSGS may progress to end-stage renal failure requiring renal
transplant. One of the greatest challenges in managing FSGS is
the recurrence risk of 30–50% after the ﬁrst transplant and
higher for subsequent grafts [2].
The glomerular ﬁltration barrier (GFB) is composed of two
cell types, the capillary endothelial cells and the podocytes,
separated by a specialized glomerular basement membrane.
In addition, mesangial cells support the structure of the
glomerulus, and parietal epithelial cells line the capsule
encircling the glomerular capillaries (Fig. 1). The cell–cellublished by Elsevier. This is an open access article under the CC BY-NC-
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as the slit diaphragm and is a highly sophisticated complex of
proteins that orchestrates signaling to the interior of the cell.
Much has been discovered about the genetics of NS since the
discovery of the gene encoding nephrin in 1998 [3]. Nephrin,
along with other proteins in the slit diaphragm, is now known to
be essential to the ﬁltration mechanism of the GFB. Mutations in
genes encoding slit diaphragm proteins have led to proteinuria
and renal failure in animal models, and have also been identiﬁed
in humans with NS. The discovery of these slit diaphragm
proteins has led to subsequent studies on podocytes identifying
both downstream pathways with effects on actin cytoskeleton
remodeling within foot processes, as well as upstream factors
involved in the pathogenesis of NS. In this review, we will
discuss the slit diaphragm proteins, the cellular pathways in the
podocyte, the control of the podocyte actin cytoskeleton, podo-
cyte motility, and the effects of current therapies for NS on the
podocyte. Finally, we will elucidate some of the current break-
throughs that are helping us to understand the nature of
circulating factors in the pathogenesis of SRNS.Podocyte physiology
The tri-layer GFB comprises of the fenestrated capillary
endothelial cells, the glomerular basement membrane, and
the podocyte. The podocyte has many unique properties that
are key to its role in ultraﬁltration.
The podocyte consists of a cell body, major processes,
secondary processes, and ﬁnely interdigitating foot processes.
The slit diaphragm membrane, which links the foot processes,
controls the ultraﬁltration of molecules by signaling to the
actin cytoskeleton within the foot processes. In addition to
the actin cytoskeleton within the foot processes, other impor-
tant structural components of the podocyte include vimentin-
rich intermediate ﬁlaments and microtubules. These compo-
nents all contribute towards cell shape and rigidity.Figure 1. Diagram of a glomerular capillary, showing the three cell t
interrelationship in supporting the glomerulus and forming the ﬁltration bMicrotubules regulate cell motility, vesicular transport, cell
polarity, and organization and positioning of the membrane
organelles. Crosstalk between actin and microtubules enables
changes at the slit diaphragm to be transmitted to the nuclei
via microtubule-associated proteins, and enables the podo-
cyte to respond to signals from the foot processes [4].
Under the cell body and its major processes lies the
subpodocyte space. This is estimated to cover 60% of the
GFB, and the level of resistance within this space (which is
controlled by tight exit pores) contributes signiﬁcantly to the
overall permeability of the GFB [5].
It is interesting that the podocyte, traditionally described as an
epithelial cell, shows several features of smooth muscle cells
when fully differentiated. It expresses smooth muscle cell mar-
kers such a smoothelin and calponin [6], and is thought to have a
contractile function [7]. It has been speculated that, instead of it
being the mesangial cell, the podocyte might have the role of
supporting capillary pressures, preventing capillary expansion
and maintaining ultraﬁltration [6].Regulation of the actin cytoskeleton
A universal pathological feature of NS is podocyte foot process
effacement, as seen by electron microscopy. The dynamic control
of the actin cytoskeleton is essential in maintaining the shape and
movement of the foot processes, as well as in maintaining cell–
cell contacts. More than a hundred proteins are involved in the
regulation of actin, enabling processes such polymerization and
depolymerization [9]. When arranged linearly as a central core of
ﬁlament bundles, actin can provide signiﬁcant tensile strength [8].
Actin branching in the form of ﬁlopodia or lamellipodia is likely
to drive cell motility, as has been seen in the growth cones of
neurons. Actinmonomers can self-assemble, but this is kinetically
unfavorable. The two important catalysts for rapid actin assembly
are formins, which enable actin ﬁlaments to elongate at a rapid
rate [10], and the actin-related protein 2/3 (Arp2/3) complex,ypes, as well as the parietal cells of Bowman’s capsule, and their
arrier.
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(WASP) family of proteins to form branched actin networks [9].
The Ena/VASP family of proteins have emerged as regulators of
actin assembly and cell motility [11].Figure 2. A schematic view of regulation of RhoGTPase activation,
and hence control of cell motility, by slit diaphragm proteins.
Asterisks represent activated forms, and lighter colored boxes inactiva-
tion or degradation. Red boxes indicate proteins associated with
familial FSGS. FSGS, focal segmental glomerulosclerosis; MCNS, mini-
mal-change nephrotic syndrome; see text for other abbreviations.Rho GTPases
The small GTPases of the Rho family (RhoA, Rac1, Cdc42) are
some of the most important proteins in regulating actin
dynamics. For example, Rac1 can stimulate Arp2/3 and promote
branched actin formation, and can also induce actin polymeriza-
tion at cell–cell junctions to strengthen cell–cell contacts [12].
The Rho GTPases cycle between two distinct conformational
states: they are active when bound to GTP and inactive when
bound to GDP [7]. The complex interplay between these small
GTPases and their tightly controlled spatial and temporal dis-
tribution play a signiﬁcant role in modulating the podocyte
cytoskeleton and cell–cell adhesion. RhoA has a role in the initial
events of protrusion and is activated at the cell edge synchronous
with edge advancement, whereas Cdc42 and Rac1 are activated
just behind the cell edge 40 seconds later than RhoA, and activate
pathways implicated in the reinforcement and stabilization of
newly expanded protrusions [13].
When a podocyte-speciﬁc, doxycycline-inducible constitu-
tively active form of RhoA was created in transgenic mice, it
enhanced actin polymerization, decreased nephrin mRNA and
protein levels, promoted podocyte apoptosis, and decreased
endogenous RhoA levels [14]. Increased RhoA activity corre-
sponded to increased levels of albuminuria and to histological
changes of FSGS and extensive foot process effacement [15].
Conversely, transgenic mice with the dominant negative form
displayed a loss of podocyte stress ﬁbers, suggesting that a basal
level of RhoA plays an important role in maintaining podocyte
structure [14]. A low level of RhoA was associated with foot
process effacement that was not evident on light microscopy, and
although most mice with low levels of RhoA had low levels of
albuminuria, a high level persisted in some mice [15]. It appears
that low levels of RhoA may play a role in minimal-change
nephropathy, but this role is not yet entirely clear.
This is just one example of how the control of the actin
cytoskeleton is regulated in the podocyte, and how disruption of
this regulation could lead to NS. This tight regulation involves
many other proteins, many of which have been identiﬁed via
studies of familial NS. Mutations in these single genes often result
in SRNS and have histological changes correlating to that of FSGS.
Most of these genes code for proteins within the slit diaphragm,
which interact with the actin cytoskeleton by signaling through
the Rho GTPases (Fig. 2).Slit diaphragm proteins
Nephrin, encoded by NPHS1, is perhaps the most important of
the slit diaphragm proteins [3]. First described in 1998, mutations
in this gene result in congenital NS of the Finnish type, which
presents withmassive proteinuria in utero and at birth. Nephrin is
a transmembrane protein with eight extracellular immunoglo-
bulin domains, a ﬁbronectin III domain, and an intracellular
domain with several tyrosine residues [16]. Phosphorylation of
these tyrosine residues by Fyn allow binding of Nck adapter
proteins, which interact with N-WASP or p21-activated kinases
(PAKs) to regulate the actin cytoskeleton [17,18]. PAKs, alongwith other molecules downstream of nephrin-like phospholipase
cg1 and phosphoinositide 3-OH kinase (PI3K), are thought to
interact with Rac1 (and Cdc42 in the case of PAK) to mediate
actin reorganization [19,20]. Nephrin is also known to interact
with IQ motif containing GTPase activating protein (IQGAP), an
effector protein for Rac1 and Cdc42, which regulates actin via the
Arp2/3 complex and formins [21].
The gene NPHS2, encoding podocin, was discovered in 2000
[22]. Mutations in NPHS2 are the most frequent cause of NS
among families with congenital (39.1%) and infantile (35.3%)
NS [23]. Podocin is a member of the stomatin protein family
and contains a lipid recognition motif that enables it to
localize to lipid rafts in the slit diaphragm. Podocin recruits
and stabilizes nephrin at these lipid microdomains, and
augments its activity by approximately twofold in vitro [24].
CD2-associated protein (CD2AP) is another slit diaphragm
protein that has been found to be recruited by podocin to lipid
rafts [25]. CD2AP-deﬁcient mice were found to have defects in
their foot processes and mesangial cell hyperplasia, and died
of renal failure by 6–7 weeks of age [26]. CD2AP, like nephrin,
has been shown to associate with PI3K. Both podocin and
CD2AP have been shown to augment nephrin-induced activa-
tion of AKT, a downstream mediator of PI3K [27].
CD2AP is recruited by Rac1 to regulate cell–cell contacts in the
podocyte [28]. Although the other Rho GTPases have not been
shown to have direct interactions with CD2AP, RhoA has now
been shown to be involved in a signaling pathway mediated by
CD2AP [29]. An elegant study demonstrated that lack of CD2AP
promoted upregulation of cytosolic cathepsin L (CatL) via trans-
location of dendrin to the nucleus, resulting in the proteolysis of
synaptopodin, dynamin, and RhoA, which regulate the actin
cytoskeleton. These cells exhibited a hypersensitivity to trans-
forming growth factor-beta-mediated apoptosis [29].
a-Actinin-4 is an actin-bundling protein required for main-
tenance of the actin cytoskeleton and podocyte adhesion.
Mutations in this protein have been reported in adult-onset
autosomal dominant FSGS [30]. A point mutation of a-actinin-
4 (K255E) associated with FSGS has been shown to disrupt
actin assembly at the junctional complexes [31]. Mutations in
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nity, hence enabling the formation of misfolded actin/a-
actinin-4 aggregates, which diverts actin from its normal
localization at stress ﬁbers and cell–cell junctions. Of note,
this mutation also confers a resistance to regulation by
calcium [32]. Studies on the corresponding mouse mutant
(K256E) have shown similar microaggregates, as well as
increased targeting of mutant protein for degradation, impair-
ment of the ubiquitin–proteosome system, increased endo-
plasmic reticulum stress, and exacerbation of apoptosis [33].
Transient receptor potential-6 channel (TRPC6) is a Ca2þ-
permeable nonselective cation channel at the slit diaphragm
that interacts with nephrin and podocin. Mutations in TRPC6
result in late-onset autosomal dominant FSGS, which, inter-
estingly, mostly results in a pathological increase in calcium
inﬂux [34]. Evidence exists that TRPC-mediated calcium
inﬂux increases RhoA activity and inhibits podocyte migra-
tion. The authors of this paper hypothesize that the excessive
calcium inﬂux associated with TRPC6 mutations may render
the podocyte too ‘‘stiff’’ to respond to cues in the environ-
ment, resulting in stress ﬁber and cytoskeleton disorganiza-
tion and cell death [35]. It has been suggested that TRPC6 may
allow the slit diaphragm to detect membrane stretch and
respond to this by remodeling the actin cytoskeleton to a
contractile state [36].Microtubules
As mentioned above, microtubules are another important
structural component of the podocyte. Members of the formin
family of proteins not only control actin dynamics, but are
also involved in the remodeling of microtubules [37]. Hence
formins have the unique ability of being able to directly
regulate and coordinate both the actin and microtubule
cytoskeletons. Mutations in inverted formin-2, a member of
the formin family, have been identiﬁed as a major cause of
autosomal-dominant FSGS, accounting for 17% of cases in one
study [38]. Six out of seven mutations found in this study
were localized to a subdomain thought to bind to IQGAP;
hence the authors suggest that a disturbance in this interac-
tion might result in disruption in the cytoskeleton [38].
Microtubules play a signiﬁcant role in cell motility, due to
their mechanical properties, their ability to transport proteins
along their tracks, and their interaction with actin and with
other proteins at the cell edge [39].Podocyte motility
As discussed above, both microtubules and actin appear to
have signiﬁcant roles in coordinating not only cell shape, but
also cell motility. There is increasing evidence that the
regulation of cell motility may also be of signiﬁcance in the
prevention of proteinuria, although the degree of motility that
is considered normal or pathological has yet to be deﬁned.
Using multiphoton imaging, movement was seen in a few
cells in an experimental model of FSGS in rats, suggesting that
motility might be present in vivo [40].
Unsurprisingly, cell motility also appears to be coordinated
by the Rho GTPases. Arhgap24, which has been found to be
mutated in an autosomal dominant form of FSGS, converts
Rac1 and Cdc42 to an inactive state and reduces cellspreading and motility [41]. Another study showed that the
urokinase receptor was required to activate avb3 integrin,
which promotes cell motility and activation of Rac1 and
Cdc42 [42]. Blockade of avb3 integrin reduces podocyte
motility in vitro and causes proteinuria in mice [42]. The
increased activity of CatL, which was upregulated in CD2AP-
deﬁcient podocytes [29], results in a hypermotile podocyte
phenotype and is associated with increased proteinuria [43].
Another regulator of RhoA is synaptopodin—an actin-asso-
ciated protein that binds to a-actinin-4 and CD2AP—which
inhibits the degradation of RhoA and promotes cell motility
[44]. TRPC6 and TRPC5 act antagonistically to mediate cell
motility, the former reducing cell migration via RhoA activa-
tion, and the latter promoting cell migration via Rac1 activa-
tion [35]. It appears that there is perhaps an optimal level of
RhoA that maintains an optimal degree of motility to prevent
proteinuria, as the lack of RhoA results in proteinuria via a
hypermotile phenotype [14,15,29,43], and the excessive acti-
vation of RhoA results in a decreased migratory phenotype
that may also result in proteinuria [14,15,35].Effects of current therapies on the podocyte
Current therapies for NS include glucocorticoids and calci-
neurin inhibitors, which are thought to act via an immuno-
suppressive mechanism. There is now increasing evidence
that these drugs actually target the podocyte, and that their
efﬁcacy in NS might in fact not only be mediated by their
immune-modulating mechanisms.
Glucocorticoids have been shown to stabilize actin struc-
tures, increase RhoA activity, and enhance recovery of podo-
cytes from puromycin aminonucleoside nephrosis in a murine
model of NS [44]. Dexamethasone in human and murine
podocytes augmented podocyte survival via manipulation of
cell cycle regulators, for example by downregulating p53 and
p21, and upregulating bcl-xL [45,46]. Another suggested
mechanism of action for dexamethasone has been in upregu-
lation and restoration of defective nephrin transport [46,47].
Above, we discussed the phosphorylation of tyrosine residues
on the intracellular domain of nephrin as part of its signaling
mechanism. Nephrin phosphorylation is decreased in puro-
mycin aminonucleoside nephrosis and in minimal-change
disease, and dexamethasone has been shown to upregulate
this phosphorylation mechanism in vitro [48].
The calcineurin inhibitor ciclosporin A is another immu-
nosuppressive agent used in NS. Its action in a model of NS
has now been shown to be independent of its effect on the
immune system [49]. Ciclosporin A prevents the dephosphor-
ylation of synaptopodin, hence preventing the degradation of
synaptopodin by CatL and stabilizing the actin cytoskeleton
[49]. It has also been suggested that calcium signaling might
mediate this pathway [50].
Rituximab is a monoclonal antibody against CD20, which is
expressed on a subset of B lymphocytes. Clinically, it has been
shown to be effective in reducing relapses in difﬁcult-to-treat
steroid-sensitive NS when compared with tacrolimus [51],
and has been shown to reduce post-transplant proteinuria
and improve glomerular ﬁltration rate in those with recurrent
FSGS undergoing kidney transplants [52]. Rituximab was
designed to be highly speciﬁc for CD20, but it appears that
it might have off-target effects on the podocyte. One study
has suggested that this is mediated by sphingomyelin
WY Ding and MA Saleem / Podocyte in Nephrotic Syndrome 91phosphodiesterase acid-like 3b (SMPDL-3b) protein, which
stabilizes the actin cytoskeleton. This study showed that
rituximab provided protection from SMPDL-3b downregula-
tion in cultured podocytes, and decreased podocyte SMPDL-
3b expression in post-transplant FSGS biopsies [52].
Several new therapies have shown potential as antiproteinuric
drugs and have been recently discussed in detail by Mathieson
[53]. One particularly interesting pathway is that of sialylation,
which confers charge on certain molecules in the podocyte, such
as podocalyxin. An accidental observation in mice with a homo-
zygous mutation for uridine diphospho-N-acetylglucosamine
2-epimerase/N-acetylmannosamine kinase showed reduced sia-
lylation of podocalyxin, segmental splitting of the glomerular
basement membrane, and effacement of the podocyte foot
processes. The administration of N-acetylmannosamine rescued
these mice with increased sialylation [54]. In another study,
angiopoietin-like-4 (Angptl4), which was found to be upregu-
lated in human and experimental NS, was deliberately over-
produced in rat podocytes. This resulted in high levels of
proteinuria and foot process effacement, whereas upregulation
of circulating Angptl4 did not show such effects. It was noticed
that the Angptl4 in NS was hyposialylated and that when N-
acetylmannosamine was introduced orally, albuminuria was
signiﬁcantly reduced by 40% [55]. This effect is very promising
and might direct the way for clinical trials.Circulating factors and its effects on the podocyte
In SRNS, that is, FSGS, there is overwhelming evidence that
a plasma circulating factor might be key to the disease
process. This ranges from evidence of recurrence of protei-
nuria within hours of a new graft being transplanted in
patients with SRNS [56], to landmark experiments on
glomerular swelling after exposure to disease plasma [57].
Post-transplantation recurrence is both a clue to the patho-
genesis and a problematic and distinct clinical feature. The
idiopathic form of the disease reoccurs in 30–50% of cases in a
newly transplanted kidney (sometimes within minutes or hour-
s)—an event not convincingly seen to occur in the genetic forms
of the disease to date. The disease can be attenuated by intensive
plasma exchange in those patients. This strongly implies that
circulating plasma contains elements that directly target the
podocyte and disrupt cytoskeletal dynamics, and it can be
reasonably implied that proteins revealed to be responsible for
genetic FSGS play a key part in the unique response of podocytes
to human plasma in disease.
Recently, using the burgeoning knowledge of podocyte
biology detailed above and the sophisticated in vitro and
in vivo tools now available [58–60], researchers have begun
to approach this disease from a new perspective. Wei et al.
discovered that levels of the circulating urokinase receptor
suPAR are elevated in recurrent FSGS, and cause podocyte foot
processes via b3 integrin in a mouse model of proteinuria [61].
We have utilized the resource of conditionally immorta-
lized human podocytes [58] and discarded disease plasma
from these patients to study altered slit diaphragm and
cytoskeletal signaling that may be speciﬁc to this disease.
We demonstrated a consistent response in which disease
plasma relocalized the Slit Diaphragm proteins nephrin, podo-
cin, and CD2AP to the cytoplasm, and caused enhanced
cellular calcium inﬂux [62]. Strikingly, this response was
entirely dependent on the presence of nephrin, thus conferringa podocyte cell speciﬁcity on this aberrant response, and
perhaps going some way to explaining why it appears that
only the podocyte is affected by abnormalities in systemically
circulating plasma. We went on to show that hemopexin, a
circulating plasma protease previously identiﬁed as a putative
‘‘circulating factor’’ in NS, causes dramatic reorganization of
actin in podocytes, which again is entirely nephrin dependent
[63].
The question that follows these observations relates to
what the downstream effects are on the cytoskeleton in
response to plasma. We have recently identiﬁed phosphor-
ylation of speciﬁc actin-regulating proteins in response to
FSGS relapse plasma, compared with remission plasma, and
that FSGS relapse plasma causes enhanced podocyte motility
compared with relapse or control plasma (unpublished data).
These disease-speciﬁc insights will help build information on
how the podocyte cytoskeleton is altered in disease, as well as
pointing towards speciﬁc receptors on the cell surface that
may be responsible for initiating the cascade of events.
A phenomenal amount has been discovered about the
molecules and pathways in the podocyte and how these are
modiﬁed in both human and animal models of NS. There are
now many potential targets for novel therapies to be devel-
oped for NS, which hopefully will be podocyte speciﬁc and
without the adverse effects of current therapies. However,
there is still much to be learnt, as it is not entirely clear how
all these pathways are linked or how tightly regulated these
molecules need to be in their normal nondiseased state.Conﬂict of interest
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